Recommendations regarding COVID-19 Vaccines

Date: 04.01.2021

PRES wishes to share its recommendations regarding the vaccination of young people with rheumatic diseases against COVID-19

  • The risk and morbidity of acquiring COVID-19 is relatively similar among healthy children and those with rheumatic diseases.


  • The new COVID -19 vaccines are approved by various health authorities for patients 16 years of age and older, and are recommended for pediatric rheumatic patients above those ages.
  • It is recommended to vaccinate patients 16 years of age and older with low disease activity or those in remission, who are treated with methotrexate and biologic therapies.
  • It is advised to consult your pediatric rheumatologist in order to assess your disease activity and medications before making a decision regarding vaccination.
  • It is important to establish registries regarding the efficacy and safety of COVID-19 vaccines for patients with pediatric rheumatic diseases.
  • It remains important to be vaccinated against influenza; however, the influenza vaccine should not be given together (best 2 weeks apart) from the COVID-19 vaccine.
  • Vaccine will most likely protect the patient from getting severe course of COVID-19, but it is still possible that vaccinated person could carry the virus and be contagious to others. Therefore, vaccinated patients should still be wearing masks and practicing physical distancing.

By continuing to browse this website, you accept cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. Find out more about our Privacy policy and how to manage them on your browser. You can change your cookie settings at any time.    

Cookie PolicyAccept